Janssen Research & Development, Llc

This study tests whether nipocalimab works better than efgartigimod for people with generalized myasthenia gravis, a condition where the immune system attacks nerve-muscle connections, causing weakness. About 115 adults will receive one of the two drugs to see which better contro…

This early-stage study tests a new drug, JNJ-95437446, in people with advanced solid tumors like lung, colorectal, or head and neck cancers that have not responded to other treatments. The main goals are to find safe doses and check for side effects. About 380 participants will t…

This study compares two drug combinations as first treatment for people with advanced left-sided colorectal cancer that cannot be removed by surgery. About 1,000 adults will receive either amivantamab plus chemotherapy or cetuximab plus chemotherapy. The goal is to see which comb…

This study is testing an experimental drug called nipocalimab in children aged 2 to 18 who have generalized myasthenia gravis, a condition that causes muscle weakness. The goal is to see if the drug can safely lower certain immune proteins (IgG) that contribute to the disease and…

This study tests whether two new drug combinations (teclistamab or talquetamab plus daratumumab and lenalidomide) work better than the current standard treatment for people newly diagnosed with multiple myeloma who cannot have a stem cell transplant. About 1,590 participants will…

This study tests a new medicine called nipocalimab against a standard treatment (IVIG) in pregnant women whose babies are at risk for a rare condition that causes low platelets and severe bleeding. The goal is to see if nipocalimab can better prevent death or serious bleeding in …

This study tests a treatment called cilta-cel, a type of CAR-T therapy, for people with multiple myeloma. The goal is to see if it can make the cancer disappear or shrink significantly. About 60 participants will receive the therapy, and researchers will check for signs of cancer…

This study tests an experimental drug called pasritamig, which helps the body's immune cells attack prostate cancer cells. It is for people with metastatic castration-resistant prostate cancer, meaning the cancer has spread and stopped responding to hormone therapy. About 663 par…

This early-stage study tests a new drug called JNJ-87890387 in people with advanced solid tumors that have spread or cannot be removed. The main goal is to find a safe dose and check for side effects. About 200 adults with certain types of kidney, ovarian, uterine, colorectal, or…

This study is testing a new treatment for bladder cancer that places a special device (TAR-210) directly into the bladder to release the drug erdafitinib. The goal is to find the best dose and see if it can shrink or eliminate tumors while keeping side effects manageable. About 2…

This early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in people with relapsed or refractory multiple myeloma or AL amyloidosis. About 180 participants will receive the drug to find the safest dose and check f…

This study tests a new treatment called JNJ-90014496 (prizlo-cel) for adults with B-cell non-Hodgkin lymphoma that has come back or not responded to other treatments. The therapy uses a patient's own immune cells, modified to target two markers on cancer cells (CD19 and CD20). Th…

This study tests whether nipocalimab can reduce lupus disease activity better than a placebo. It involves 600 adults with moderate to severe lupus. The main goal is to see how many people achieve a meaningful reduction in symptoms after 52 weeks of treatment.

This study tests a new drug, bleximenib, for people with acute leukemia that has come back or not responded to other treatments. The drug targets specific genetic changes in leukemia cells. The study has two phases: first to find the best dose and check safety, then to see how we…

This study tests a new drug called JNJ-79635322 in people with multiple myeloma that has returned or stopped responding after at least 3 prior treatments. The goal is to see if the drug can shrink tumors or slow the cancer. About 157 participants will receive the drug, and resear…

This study tests a drug called guselkumab in 120 children with moderate to severe Crohn's disease. The goal is to see if the drug can reduce symptoms and heal the gut lining after one year of treatment. Participants must have active Crohn's disease confirmed by endoscopy. The stu…

This study tests whether adding pasritamig (a drug that helps immune cells attack cancer) to standard chemotherapy (docetaxel) can delay cancer growth in men with metastatic castration-resistant prostate cancer. About 800 participants will receive either the combination or chemot…

This study looks at how well a combination of two drugs, ibrutinib and venetoclax, works for people with chronic lymphocytic leukemia (CLL) when used in regular medical practice. About 60 adults who need treatment for CLL will take these pills for a set period of time. The main g…

This study is testing a drug called amivantamab, either alone or with standard chemotherapy, in people with advanced colorectal cancer that has spread. The goal is to see if the drug can shrink tumors and to find the safest dose when combined with chemo. About 225 adults with spe…

This study tests how well the drug guselkumab improves symptoms of psoriatic arthritis, a condition causing joint pain and skin patches. Researchers will use ultrasound to measure joint inflammation in 200 participants over 24 weeks. The goal is to see if guselkumab reduces swell…

This study tests a new drug (JNJ-79635322) combined with standard treatments for multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective dose. About 140 adults with multiple myeloma will participate. This is an early-stage trial focused on safe…

This early-phase study tests an experimental drug, JNJ-88549968, designed to help the immune system attack cancer cells with a specific genetic change (CALR mutation). About 220 adults with essential thrombocythemia or myelofibrosis will receive the drug to find a safe dose and c…

This early-phase study tests whether combining two experimental antibodies (JNJ-87189401 and JNJ-78278343) can help control advanced prostate cancer that has spread or is no longer responding to standard treatments. About 355 men with advanced prostate cancer will take part. The …

This study tests two new drug combinations (Tal-P and Tal-Tec) against standard treatments for people with multiple myeloma that has come back or stopped responding after 1 to 4 prior therapies. About 795 adults will take part. The goal is to see which combination works better at…

This early-phase study tests a new drug, JNJ-87562761, in people with multiple myeloma whose cancer has returned or stopped responding to prior treatments. The main goals are to find a safe dose and check for side effects. About 80 participants will take part in this first-in-hum…

This study tests an oral medication called icotrokinra for people with moderate to severe ulcerative colitis, a chronic condition causing colon inflammation and ulcers. Researchers will see if the drug can bring about remission—meaning fewer bathroom trips, less bleeding, and hea…

This early-phase study tests an experimental drug called JNJ-95566692, a trispecific antibody designed to attach to three targets on lymphoma cells and immune cells to help the body fight the cancer. About 130 adults with B-cell non-Hodgkin lymphoma that has returned or not respo…

This study tests a medicine called nipocalimab to see if it can lower the risk of severe bleeding or death in unborn babies with a rare condition called FNAIT, where the mother's immune system attacks the baby's platelets. The trial enrolls pregnant women who have had a previous …

This early-stage study tests a new drug, JNJ-90189892, in about 155 people whose acute myeloid leukemia or myelodysplastic neoplasms have not responded to treatment or have returned. The goal is to find a safe dose and see if the drug works, alone or with other medicines. Partici…

This study tests a drug called bedaquiline, given together with other TB medicines, in children and teens (birth to under 18 years) who have multidrug-resistant tuberculosis (MDR-TB). The goal is to see how safe the drug is, how the body processes it, and whether it helps fight t…

This study tests an experimental drug called JNJ-95597528 in adults with moderate to severe atopic dermatitis (eczema). About 180 participants will receive either the drug or a placebo to see if it improves skin symptoms like redness, thickness, and itching. The main goal is to m…

This study tests a new drug, JNJ-88545223, in 240 adults with active psoriatic arthritis (PsA) to see if it reduces joint pain and skin symptoms better than a placebo. Participants receive either the drug or a placebo for 16 weeks, and doctors measure improvements in joint swelli…

This study tests an experimental drug called JNJ-89862175 in people with advanced solid tumors (lung, kidney, ovarian, or uterine cancers that have spread). The goal is to find a safe dose and check for side effects. About 360 participants will take part in two phases: first to f…

This study compares a new drug delivery system, TAR-210, to standard chemotherapy for people with a certain type of bladder cancer that hasn't spread into the muscle. The TAR-210 system delivers erdafitinib directly into the bladder, targeting tumors with specific genetic changes…

This study tests whether the experimental drug icotrokinra can reduce symptoms and intestinal inflammation in people with moderate-to-severe Crohn's disease. About 1,092 participants will receive either icotrokinra or a placebo. The goal is to see if the drug leads to clinical re…

This early-stage study tests a new drug (JNJ-78278343) combined with other treatments for men whose prostate cancer has spread and no longer responds to hormone therapy. The goal is to find the safest and most effective dose and to monitor side effects. About 300 participants wil…

This study offers ongoing access to the drug ibrutinib for people with certain blood cancers (like chronic lymphocytic leukemia or mantle cell lymphoma) who are already taking it and benefiting. Researchers will track side effects and disease changes over time. About 700 particip…

This study tests whether adding the drug amivantamab to standard chemotherapy and immunotherapy can help people with advanced head and neck cancer live longer. About 500 adults whose cancer has spread or returned and who have not had prior treatment for this stage will participat…

This study tests a new drug called icotrokinra (JNJ-77242113) for people with active psoriatic arthritis, a condition causing joint pain and skin patches. About 750 adults who have tried other treatments will receive either the drug or a placebo. The goal is to see if the drug re…

This study offers ongoing treatment with daratumumab for up to 500 adults with multiple myeloma who are already benefiting from it in earlier studies. The goal is to keep providing the drug while monitoring long-term safety, such as serious side effects and infections. Participan…

This study tests two approaches for people with untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma: a combination of ibrutinib and venetoclax, or ibrutinib alone. The key idea is to adjust the ibrutinib dose—either by starting lower or changing it based on…

This early-phase study tests an experimental drug called JNJ-89402638 in people with advanced colorectal or stomach cancer that has spread and not responded to prior treatments. The study aims to find the safest dose and check if combining the drug with standard therapies like be…

This study tests whether adding the experimental drug bleximenib to standard treatment (venetoclax and azacitidine) helps people with a specific genetic subtype of acute myeloid leukemia (AML) achieve remission and live longer. About 600 adults aged 18 and older who are newly dia…

This study tests whether adding the drug amivantamab to standard chemotherapy (FOLFIRI) helps people with a certain type of advanced colorectal cancer live longer without the disease getting worse. About 700 adults whose cancer has returned or spread and who have already had chem…

This early-stage study tests a new combination of two experimental drugs for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The first drug helps the immune system target cancer cells, while the second delivers a toxin directly to them…

This study tests an experimental drug called nipocalimab in about 199 adults with generalized myasthenia gravis, a condition that causes muscle weakness. Participants receive either nipocalimab or a placebo to see if the drug improves daily activities like talking, chewing, and b…

This study follows 150 people with early-stage bladder cancer (NMIBC) who are receiving a treatment called TAR-200. Researchers want to see how long it takes for the cancer to come back or get worse in real-world settings. The goal is to understand how well TAR-200 works outside …

This early-phase study tests a new combination of two drugs for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The first drug helps the body's immune cells attack cancer cells, while the second aims to boost that attack. About 40 part…

This study tests a medicine called nipocalimab in pregnant people whose babies are at high risk for a severe blood condition (HDFN) that can cause dangerous anemia. The goal is to see if the drug can prevent the need for blood transfusions in the womb and reduce the risk of death…

This study tests whether guselkumab works better than risankizumab for people with moderate to severe Crohn's disease, a condition that causes painful gut inflammation. About 530 adults will receive one of the two drugs and be followed for a year. The main goal is to see who achi…

This study tests a drug called amivantamab, alone or with other treatments, in people with head and neck cancer that has come back or spread. About 287 adults will take part to see if the drug shrinks tumors and is safe. The goal is to find better ways to control the disease.

This study tests a new drug, JNJ-79635322, against another targeted therapy for people with multiple myeloma that has returned or stopped responding after at least three prior treatments. About 400 participants will be randomly assigned to one of the two treatments. The goal is t…

This study tests a new treatment called TAR-210 (a drug placed directly into the bladder) against standard chemotherapy for people with a high-risk type of bladder cancer that has certain genetic changes (FGFR alterations). Participants have already received BCG therapy. The goal…

This study tests a combination of two drugs, amivantamab and olomorasib, in people with a specific type of advanced lung cancer (KRAS G12C mutation) that has spread. The goal is to find the best dose and see if the combo can shrink tumors or slow their growth. About 60 participan…

This study tests a new drug called talquetamab for people with multiple myeloma, a type of blood cancer, that has returned or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. About 510 participants will receive the drug to see…

This study looks at the long-term safety of a drug called guselkumab in children who have Crohn's disease, ulcerative colitis, or juvenile psoriatic arthritis. About 196 kids who already completed a previous study and benefited from the drug will continue treatment. The main goal…

This study tests whether a new drug, seltorexant, can improve mood in people with major depression who also have trouble sleeping. About 600 adults will receive either the drug or a placebo for several weeks, then all can take the drug in an extended safety phase. The goal is to …

This study tests whether a nasal spray containing esketamine, given alongside standard care, can quickly reduce symptoms of major depression and suicidal thoughts in teenagers. About 258 adolescents with acute suicidal behavior will receive either the spray or a placebo. The main…

This study tests a drug called seltorexant, taken with standard antidepressants, to see if it improves depression and sleep in people with major depression and insomnia. About 752 adults and elderly who haven't fully responded to their current antidepressant will receive either s…

This study tests whether a new drug called JNJ-89495120 can reduce depression symptoms better than a placebo. About 100 adults with major depressive disorder will take the drug or a placebo for a few days. The main goal is to see if symptoms improve within 5 days.

This study tests if certain preventive treatments can reduce or prevent taste changes caused by the drug talquetamab in people with multiple myeloma. About 210 participants will be randomly assigned to different preventive strategies. The goal is to improve quality of life by min…

This study observes about 380 people with a common type of advanced lung cancer caused by an EGFR gene change. Participants receive amivantamab as part of their normal care. Researchers will track how long people stay on treatment and how long the cancer is controlled, aiming to …

This study aims to understand sleep patterns in people with major depressive disorder, comparing those with moderate-to-severe insomnia to those with little or no insomnia. About 80 participants will wear a headband at home that records brain activity during sleep, and also fill …

This study looks at how the body absorbs, breaks down, and gets rid of a radioactive form of the drug bleximenib in 10 people with acute leukemia. Participants have a type of leukemia that has come back or not responded to other treatments. The goal is to understand the drug's pa…